US Stock MarketDetailed Quotes
CTMX CytomX
- 1.000
- -0.050-4.76%
Trading Nov 4 15:22 ET
78.12MMarket Cap6.67P/E (TTM)
1.070High0.993Low818.22KVolume1.050Open1.050Pre Close833.82KTurnover1.23%Turnover RatioLossP/E (Static)78.12MShares5.85052wk High-2.50P/B66.34MFloat Cap0.98852wk Low--Dividend TTM66.34MShs Float35.000Historical High--Div YieldTTM7.34%Amplitude0.988Historical Low1.019Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
CytomX Stock Forum
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
Striding towards revolutionizing cancer therapy, CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced a clinical trial collaboration and supply agreement with pharmaceutical giant Merck (known as MSD outside of the US and Canada). This collaboration is set to explore the therapeutic potential of CX-801, a novel, dually-m...
No comment yet